Merck (MRK) Shares Outstanding (2009 - 2026)
Merck (MRK) reported Shares Outstanding of $3.6 billion for Q1 2026, little changed year-over-year from $3.6 billion in Q1 2025, and little changed quarter-over-quarter from $3.6 billion in Q4 2025.
Merck (MRK) Shares Outstanding (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Shares Outstanding data on file, last reported at $3.6 billion in Q1 2026.
- Shares Outstanding for Q1 2026 came in at $3.6 billion, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 billion (changed 0.0% YoY), and the FY2025 annual result was $3.6 billion, changed 0.0% from the prior year.
- Shares Outstanding was little changed at $3.6 billion in Q1 2026 per MRK's latest filing, from $3.6 billion in the prior quarter.
- Over five years, Shares Outstanding peaked at $3.6 billion in Q3 2025 and troughed at $3.6 billion in Q1 2022.
- A 5-year average of $3.6 billion and a median of $3.6 billion in 2022 frame the typical range for Shares Outstanding.
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding changed 0.0% in 2022, then increased 0.0% in 2025.
- A 5-year view of Shares Outstanding shows it stood at $3.6 billion in 2022, then changed by 0.0% to $3.6 billion in 2023, then changed by 0.0% to $3.6 billion in 2024, then increased by 0.0% to $3.6 billion in 2025, then changed by 0.0% to $3.6 billion in 2026.
- Business Quant data shows MRK's Shares Outstanding at $3.6 billion in Q1 2026, $3.6 billion in Q4 2025, and $3.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 943.50 Mn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 3.12 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 1.77 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 3.58 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 539.70 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 1.24 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 9.64 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.92 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.58 Bn |
| Mar 31, 2026 | 3.58 Bn |
| Mar 31, 2026 | 3.58 Bn |
| Mar 31, 2026 | 3.58 Bn |
| Mar 31, 2026 | 3.58 Bn |
| Mar 31, 2026 | 3.58 Bn |
| Mar 31, 2026 | 3.58 Bn |
| Mar 31, 2026 | 3.58 Bn |
| Dec 31, 2025 | 3.58 Bn |
| Dec 31, 2025 | 3.58 Bn |
| Dec 31, 2025 | 3.58 Bn |
| Dec 31, 2025 | 3.58 Bn |
| Dec 31, 2025 | 3.58 Bn |
| Dec 31, 2025 | 3.58 Bn |
| Dec 31, 2025 | 3.58 Bn |
| Dec 31, 2025 | 3.58 Bn |
| Sep 30, 2025 | 3.58 Bn |
| Sep 30, 2025 | 3.58 Bn |
| Sep 30, 2025 | 3.58 Bn |
| Sep 30, 2025 | 3.58 Bn |